Literature DB >> 18657098

Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.

Ties Hoomans1, Elisabeth A L Fenwick, Steve Palmer, Karl Claxton.   

Abstract

OBJECTIVE: In a budget-constrained health-care system, decisions about investing in strategies to promote implementation have to be made alongside decisions about health-care provision and research funding. Using a Bayesian decision-theoretic approach, an analytic framework has been developed to inform these separate but related decisions, establishing the expected value of both perfect information (EVPI) and perfect implementation (EVPIM). We applied this framework to inform decision-making about resource allocation to metastatic hormone-refractory prostate cancer (mHRPC) in the UK.
METHODS: Based on available evidence on the cost-effectiveness of all plausible treatments for mHRPC, we determined which treatment option(s) were cost-effective and explored the uncertainty surrounding this decision. Given the decision uncertainty and the variation in care provided by health-care professionals, we then determined the EVPI and EVPIM. Finally, we performed sensitivity analyses to explore the influence of alternative assumptions regarding various decision parameters on the efficiency of resource allocation.
RESULTS: Depending on the cost-effectiveness threshold (lambda), we identified mitoxantrone plus prednisone/prednisolone and docetaxel plus prednisone/prednisolone (3 weekly) as the optimal treatments for mHRPC. Given current clinical practice, there appears to be considerable scope for improving the efficiency of health-care provision: the EVPI (estimated to be over pound13 million) indicates that acquiring further information could be cost-effective; and the EVPIM (estimated to be over pound4 million) suggests that investing in strategies to implement the treatments regimens being identified as optimal is potentially worthwhile. Through sensitivity analyses, we found that the EVPI and EVPIM are mainly driven by lambda, the number of treatment options being considered, the current level of implementation, and the size of the eligible patient population.
CONCLUSION: The application demonstrates that the framework provides a simple and useful analytic tool for decision-makers to address resource allocation problems between health-care provision, further research, and implementation efforts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657098     DOI: 10.1111/j.1524-4733.2008.00431.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  18 in total

1.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

2.  Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.

Authors:  Laura McCullagh; Susanne Schmitz; Michael Barry; Cathal Walsh
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

3.  Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.

Authors:  Louisa G Gordon; Nicholas G Hirst; George C Mayne; David I Watson; Timothy Bright; Wang Cai; Andrew P Barbour; Bernard M Smithers; David C Whiteman; Simon Eckermann
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

4.  Quantitative Methods for Valuing Comparative Effectiveness Information.

Authors:  Anirban Basu; David Meltzer
Journal:  Biopharm Rep       Date:  2010

5.  Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling.

Authors:  Hawre Jalal; Jeremy D Goldhaber-Fiebert; Karen M Kuntz
Journal:  Med Decis Making       Date:  2015-04-03       Impact factor: 2.583

Review 6.  Methods in comparative effectiveness research.

Authors:  Katrina Armstrong
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

Review 8.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

9.  Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.

Authors:  Caroline S Bennette; David L Veenstra; Anirban Basu; Laurence H Baker; Scott D Ramsey; Josh J Carlson
Journal:  Med Decis Making       Date:  2016-03-24       Impact factor: 2.583

10.  The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial.

Authors:  David M Meads; Andrea Marshall; Claire T Hulme; Janet A Dunn; Hugo E R Ford
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.